The Lavender trial was paused for three months due to Covid, the progress would be slowed down by the Covid.
Here's the Key Dates for the LAVENDER Study:
September 15, 2019: The study protocol, detailing the trial’s design, objectives, and methodology, was finalized.
October 1, 2019: The U.S. Food and Drug Administration (FDA) approved the trial, allowing it to proceed.
October 30, 2019: The first participant was enrolled, marking the official start of the study.
March 16, 2020 – June 15, 2020: The trial was paused for three months due to the COVID-19 pandemic, likely to ensure participant safety and comply with restrictions.
November 30, 2021: The last patient completed their participation, concluding the treatment and data collection phase.
December 6, 2021: Acadia Pharmaceuticals announced positive top-line results, indicating that trofinetide met its primary endpoints.
NEU Price at posting:
$13.23 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)